161 related articles for article (PubMed ID: 36983070)
1. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation.
Molteni E; Baldan F; Damante G; Allegri L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983070
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells.
Allegri L; Capriglione F; Maggisano V; Damante G; Baldan F
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360846
[TBL] [Abstract][Full Text] [Related]
3. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
4. Reevaluation of bromodomain ligands targeting BAZ2A.
Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
[TBL] [Abstract][Full Text] [Related]
5. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
6. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Bevill SM; Olivares-Quintero JF; Sciaky N; Golitz BT; Singh D; Beltran AS; Rashid NU; Stuhlmiller TJ; Hale A; Moorman NJ; Santos CM; Angus SP; Zawistowski JS; Johnson GL
Mol Cancer Res; 2019 Jul; 17(7):1503-1518. PubMed ID: 31000582
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
[TBL] [Abstract][Full Text] [Related]
8. 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Clinckspoor I; Verlinden L; Overbergh L; Korch C; Bouillon R; Mathieu C; Verstuyf A; Decallonne B
J Steroid Biochem Mol Biol; 2011 Mar; 124(1-2):1-9. PubMed ID: 21182945
[TBL] [Abstract][Full Text] [Related]
9. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
10. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
11. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
12. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
[TBL] [Abstract][Full Text] [Related]
14. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.
Onoda N; Sugino K; Higashiyama T; Kammori M; Toda K; Ito K; Yoshida A; Suganuma N; Nakashima N; Suzuki S; Tsukahara K; Noguchi H; Koizumi M; Nemoto T; Hara H; Miyauchi A; Sugitani I
Thyroid; 2016 Sep; 26(9):1293-9. PubMed ID: 27484330
[TBL] [Abstract][Full Text] [Related]
16. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
[TBL] [Abstract][Full Text] [Related]
18. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
19. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Tang J; Tian Z; Liao X; Wu G
Int J Biol Sci; 2021; 17(2):417-429. PubMed ID: 33613102
[TBL] [Abstract][Full Text] [Related]
20. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
